

New York State Medicaid Drug Utilization Board Meeting Agenda

The Drug Utilization (DUR) Board will meet April 24, 2014, from
9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza,
Albany, New York

Agenda Items

Preferred Drug Program (PDP)

The DUR Board will review therapeutic classes, described and listed below, as they pertain to the PDP. The therapeutic classes to be reviewed contain new relevant clinical and/or financial information. Therapeutic classes not included on this agenda may be reviewed at a later date.

- The Board will review new clinical and financial information as required, to recommend preferred and non-preferred drugs. ^
- The Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.
- New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.
- Those wishing to submit new clinical information must do so in an electronic format by April 9, 2014 or the Board may not have ample time to review the information.

^ The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

1. Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

(Previous review date: April 19, 2012)

Drugs Affected: Anaprox (naproxen sodium), Anaprox DS (naproxen sodium DS), Arthrotec (diclofenac sodium/misoprostol), Cambia (diclofenac potassium), Cataflam (diclofenac potassium), Celebrex (celecoxib), Daypro (oxaprozin), diclofenac potassium, diclofenac sodium, diclofenac sodium XR, diclofenac/misoprostol, diflunisal, Duexis (ibuprofen/famotidine), etodolac, etodolac ER, Feldene (piroxicam), fenoprofen, Flector Patch (diclofenac epolamine), flurbiprofen, ibuprofen, Indocin (indomethacin), indomethacin, indomethacin SR, ketoprofen, ketoprofen SA, ketorolac, meclufenamate, mefenamic acid, meloxicam, Mobic (meloxicam), nabumetone, Naprelan (naproxen sodium CR), Naprosyn (naproxen), Naprosyn EC (naproxen EC), naproxen, naproxen EC, naproxen sodium, oxaprozin, Pennsaid (diclofenac sodium topical solution), piroxicam, Ponstel (mefenamic acid), Sprix (ketorolac tromethamine), sulindac, tolmetin, Vimovo (naproxen and esomeprazole magnesium), Voltaren XR (diclofenac sodium DR), Voltaren Gel (diclofenac sodium), Zipsor (diclofenac potassium), Zorvolex (diclofenac)

2. Opioids - Long Acting

(Previous review date: June 27, 2013)

Drugs Affected: Avinza (morphine sulfate ER), Butrans (buprenorphine), Conzip (tramadol ER), Duragesic (fentanyl patch), Exalgo (hydromorphone HCL ER), fentanyl patch, Kadian (morphine sulfate SR), morphine sulfate SR/ER, MS Contin (morphine sulfate CR), Nucynta ER (tapentadol ER), Opana ER (oxymorphone ER), Oxycontin (oxycodone HCl CR), oxymorphone ER, Ryzolt ER (tramadol ER), tramadol ER, Ultram ER (tramadol ER), Zohydro ER (hydrocodone ER)

3. Hepatitis C - Direct Acting Antivirals

(Previous review date: June 27, 2013)

Drugs Affected: Copegus (ribavirin), Incivek (telaprevir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Victrelis (boceprevir)

4. Anticonvulsants - Second Generation

(Previous review date: June 27, 2013)

Drugs Affected: Banzel (rufinamide), felbamate, Felbatol (felbamate), Fycompa (perampanel), gabapentin, Gabitril (tiagabine), Keppra/Keppra XR (levetiracetam), Lamictal/Lamictal XR(lamotrigine), lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, Lyrica (pregablin), Neurontin (gabapentin), Onfi (clobazam), Potiga (ezogabine), Sabril (vigabatrin), tiagabine, Topamax (topiramate), Topiragen (topiramate), topiramate, Trokendi XR (topiramate ER), Vimpat (lacosamide), Zonegran (zonisamide), zonisamide

5. Antipsychotics – Second Generation

(Previous review date: April 19, 2012)

Drugs Affected: Abilify (aripiprazole), clozapine/clozapine ODT, Clozaril (clozapine), Fanapt (iloperidone), FazaClo (clozapine), Geodon (ziprasidone), Invega (paliperidone), Latuda (lurasidone), olanzapine/olanzapine ODT, quetiapine, risperidone, Risperdal (risperidone), Saphris (asenapine), Seroquel (quetiapine), Seroquel XR (quetiapine), Versacloz (clozapine), ziprasidone, Zyprexa (olanzapine)

6. Carbamazepine Derivatives

(Previous review date: June 27, 2013)

Drugs Affected: Aptiom (eslicarbazepine), carbamazepine, carbamazepine ER/XR, Carbatrol (carbamazepine ER), Equetro (carbamazepine ER), oxcarbazepine, Oxtellar XR (oxcarbazepine XR), Tegretol (carbamazepine), Tegretol XR (carbamazepine XR), Trileptal (oxcarbazepine), Epitol (carbamazepine),

7. Central Nervous System Stimulants

(Previous review date: April 19, 2012)

Drugs Affected: Adderall (amphetamine salt combo), Adderall XR (amphetamine salt combo XR), amphetamine salt combo ER, amphetamine salt combo IR, Concerta (methylphenidate), Daytrana (methylphenidate), Desoxyn (methamphetamine), Dexedrine Spansule (dextroamphetamine), dexamethylphenidate, dexamethylphenidate XR, dextroamphetamine sulfate, dextroamphetamine sulfate ER, Focalin (dexamethylphenidate), Focalin XR (dexamethylphenidate XR), Metadate CD (methylphenidate CD), Metadate ER (methylphenidate ER), methamphetamine, Methylin (methylphenidate), methylphenidate, methylphenidate CD/ER/SR, modafinil, Nuvigil (armodafinil), Procentra (dextroamphetamine sulfate), Provigil (modafinil), Quillivant XR (methylphenidate), Ritalin (methylphenidate), Ritalin LA (methylphenidate LA), Ritalin SR (methylphenidate SR), Vyvanse (lisdexamfetamine dimesylate), ZenZedi (dextroamphetamine)

8. Multiple Sclerosis Agents

(Previous review date: June 27, 2013)

Drugs Affected: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate)

9. Selective Serotonin Reuptake Inhibitors (SSRIs)

(Previous review date: June 27, 2013)

Drugs Affected: Brintellix (vortioxetine), Brisdelle (paroxetine mesylate), Celexa (citalopram), citalopram, escitalopram, fluoxetine, fluoxetine DR, fluvoxamine, fluvoxamine ER, Lexapro (escitalopram), Luvox CR (fluvoxamine), paroxetine, paroxetine CR, Paxil (paroxetine), Paxil CR (paroxetine HCL CR), Pexeva (paroxetine mesylate), Prozac (fluoxetine), Sarafem (fluoxetine), sertraline, Viibryd (vilazodone), Zoloft (sertraline)

10. Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)

(Previous review date: April 19, 2012)

Drugs Affected: Cymbalta (duloxetine), desvenlafaxine, Effexor XR (venlafaxine ER), Fetzima (levomilnacipran), Khedezla (desvenlafaxine), Pristiq (desvenlafaxine succinate), Savella (milnacipran), venlafaxine, venlafaxine ER

11. Antifungals - topical

(Previous review date: June 16, 2011)

Drugs Affected: Ciclodan (ciclopirox), ciclopirox olamine, clotrimazole, clotrimazole/betamethasone, econazole nitrate, Ertaczo (sertaconazole nitrate), Exelderm (sulconazole nitrate), Extina (ketoconazole), ketoconazole, Ketodan (ketoconazole), Lamisil AT (terbinafine HCL), Loprox (ciclopirox), Lotrisone (clotrimazole/betamethasone), Luzu (luliconazole), Mentax (butenafine HCL), miconazole nitrate, Naftin (naftifine HCL), Nyamyc (nystatin), nystatin, nystatin/triamcinolone, Nystop (nystatin), Oxistat (oxiconazole nitrate), Pedi-Dri (nystatin), terbinafine, tolnaftate, Vusion (miconazole nitrate/zinc).

12. Anti-infectives - topicals

(Previous review date: June 27, 2013)

Drugs Affected: Acanya (clindamycin/benzoyl peroxide), Akne-Mycin (erythromycin), Benzaclin (clindamycin/benzoyl peroxide), Benzamycin (erythromycin/benzoyl peroxide), Cleocin T (clindamycin), Clindacin P (clindamycin), Clindagel (clindamycin), clindamycin phosphate, clindamycin/benzoyl peroxide, Duac (clindamycin/benzoyl peroxide), erythromycin, erythromycin/benzoyl peroxide, Evoclin (clindamycin)

13. Growth Hormones

(Previous review date: June 27, 2013)

Drugs Affected: Genotropin (somatropin), Humatrope (somatropin), Norditropin (somatropin), Nutropin/Nutropin AQ (somatropin), Omnitrope (somatropin), Saizen (somatropin), Tev-Tropin (somatropin), Zorbtive (somatropin)

14. Thiazolidinediones (TZDs)

(Previous review date: June 16, 2011)

Drugs Affected: Actoplus Met (pioglitazone/metformin), Actoplus Met XR (pioglitazone/metformin), Actos (pioglitazone), Avandamet (rosiglitazone/metformin), Avandaryl (rosiglitazone/glimepiride), Avandia (rosiglitazone), Duetact (pioglitazone/glimepiride), pioglitazone, pioglitazone/glimepiride, pioglitazone/metformin.

15. Sulfasalazine Derivatives

(Previous review date: June 15, 2012)

Drugs Affected: Apriso (mesalamine), Asacol, Asacol HD (mesalamine), Azulfidine (sulfasalazine), Azulfidine Entab (sulfasalazine DR/EC), balsalazide, Colazal (balsalazide), Delzicol DR (mesalamine), Dipentum (olsalazine), Giazol (balsalazide), Lialda (mesalamine), Pentasa (mesalamine), sulfasalazine DR/EC, sulfasalazine IR, sulfazine, sulfazine EC

16. Platelet Inhibitors

(Previous review date: June 27, 2013)

Drugs Affected: Aggrenox (dipyridamole ER/aspirin), Brilinta (ticagrelor), clopidogrel, dipyridamole, Effient (prasugrel), Persantine (dipyridamole), Plavix (clopidogrel), ticlopidine

17. Immunomodulators - Systemic

(Previous review date: June 27, 2013)

Drugs Affected: Actemra (tocilizumab subQ), Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Kineret (anakinra), Orencia (abatacept subQ), Simponi (golimumab), Stelara (ustekinumab), Xeljanz (tofacitinib)

18. Alpha-2 Adrenergic Agonist – Ophthalmic (for glaucoma)

(Previous review date: June 11, 2010)

Drugs Affected: Alphagan P (brimonidine), apraclonidine, brimonidine, Iopidine (apraclonidine), Simbrinza (brimonidine/brinzolamide)

19. Prostaglandin Agonists - Ophthalmic

(Previous review date: June 15, 2012)

Drugs Affected: latanoprost, Lumigan (bimatoprost), Rescula (unoprostone isopropyl), Travatan Z (travoprost), travoprost, Xalatan (latanoprost), Zioptan (tafluprost)

20. Phosphate Binders/Regulators

(Previous review date: June 15, 2012)

Drugs Affected: calcium acetate, Eliphos (calcium acetate), Fosrenol (lanthanum carbonate), Phoslo (calcium acetate), Phoslyra (calcium acetate), Renagel (sevelamer HCL), Renvela (sevelamer carbonate), Velphoro (sucroferric oxyhydroxide)

21. Anticholinergics/COPD Agents

(Previous review date: June 27, 2013)

Drugs Affected: Anoro Ellipta (umeclidinium/vilanterol), Atrovent HFA (ipratropium), Combivent Respimat (ipratropium/albuterol), Daliresp (roflumilast), Duoneb (ipratropium/albuterol), ipratropium, ipratropium/albuterol, Spiriva (tiotropium), Tudorza Pressair (aclidium bromide)

22. Antihistamines – second generation

(Previous review date: June 27, 2013)

Drugs Affected: cetirizine/cetirizine-D OTC, cetirizine Rx, Clarinex/Clarinex-D (desloratadine/desloratadine PSE), Claritin/Claritin-D, desloratadine, fexofenadine, levocetirizine, loratadine/loratadine D OTC, Xyzal (levocetirizine)

23. Corticosteroids - Inhaled

(Previous review date: June 27, 2013)

Drugs Affected: Aerospan (fluticasone), Alvesco (ciclesonide), Asmanex (mometasone), Flovent Diskus (fluticasone), Flovent HFA (fluticasone), Pulmicort Flexhaler (budesonide), QVAR (beclomethasone)

24. Corticosteroid/Long Acting Beta Agonist Combinations

(Previous review date: April 19, 2012)

Drugs Affected: Advair Diskus (fluticasone/salmeterol), Advair HFA (fluticasone/salmeterol), Breo Ellipta (fluticasone/vilanterol), Dulera (mometasone furoate/formoterol fumarate dihydrate), Symbicort (budesonide/formoterol)

25. Corticosteroids - intranasal

(Previous Review date: June 27, 2013)

Drugs Affected: Beconase AQ (beclomethasone dipropionate), Dymista (azelastine hydrochloride and fluticasone propionate), Flonase (fluticasone propionate), flunisolide, fluticasone propionate, Nasacort AQ (triamcinolone acetonide), Nasonex (mometasone furoate), Omnaris (ciclesonide), QNASL (beclomethasone), Rhinocort Aqua (budesonide), triamcinolone, Veramyst (fluticasone furoate), Zetonna (ciclesonide)

Agenda Timeline (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome, Introductions and DOH Updates
9:15 - 10:45	Public Comment Period
10:45 - 12:30	Clinical reviews
12:30 - 1:30	Lunch Break/Executive Session (PDP financial reviews)
1:30 - 1:45	Recommendations
1:45 - 3:00	Clinical reviews (cont.)
3:00 - 3:30	Executive Session (PDP financial reviews)
3:30 - 3:45	Recommendations (cont.)
3:45 - 4:30	Final Comments and Adjournment

Interested parties must notify the Department of Health (DoH) by April 16, 2014 of their request to address the Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing dur@health.state.ny.us. (Please reference DUR Board Speaker Request).

Public comments are limited to therapeutic classes on the agenda and new clinical information for the PDP classes under review. Comments must be brief (2 minutes) and the total comment period will not exceed ninety (90) minutes. DoH reserves the right to limit the number of interested parties providing public comment in order to meet timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by April 16, 2014. Written statements should summarize key points and may not exceed two (2) pages in length.

Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by April 9, 2014, or the Board may not have ample time to review the information. For the therapeutic classes currently subject

to the PDP, submitted clinical information must be new since the previous review of the therapeutic class.

Any information regarding the DUR Board must be sent to the DoH to ensure distribution to all members. Interested parties should not contact or send any information directly to DUR Board members.

Posted: 03/25/2014